Benzinga | Mar 3, 2021 09:23AM EST

Cantor Fitzgerald Maintains Overweight on Arena Pharmaceuticals, Lowers Price Target to $100

Cantor Fitzgerald analyst Alethia Young maintains Arena Pharmaceuticals (NASDAQ:ARNA) with a Overweight and lowers the price target from $106 to $100.